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Abstract
Curcumin has been shown to mitigate cancer phenotypes such as invasive migration, prolif-
eration, and survival by disrupting numerous signaling pathways. Our previous studies
showed that curcumin inhibits integrin β4 (ITG β4)-dependent migration by blocking interac-
tion of this integrin with growth factor receptors in lipid rafts. In the current study, we investi-
gated the possibility that curcumin inhibits ITG β4 palmitoylation, a post-translational
modification required for its lipid raft localization and signaling activity. We found that the
levels of ITG β4 palmitoylation correlated with the invasive potential of breast cancer cells,
and that curcumin effectively reduced the levels of ITG β4 palmitoylation in invasive breast
cancer cells. Through studies of ITG β4 palmitoylation kinetics, we concluded curcumin
suppressed palmitoylation independent of growth factor-induced phosphorylation of key
ITG β4 Ser and Tyr residues. Rather, curcumin blocked autoacylation of the palmitoyl acyl-
transferase DHHC3 that is responsible for ITG β4 palmitoylation. Moreover, these data re-
veal that curcumin is able to prevent the palmitoylation of a subset of proteins, but not
indiscriminately bind to and block all cysteines from modifications. Our studies reveal a
novel paradigm for curcumin to account for much of its biological activity, and specifically,
how it is able to suppress the signaling function of ITG β4 in breast cancer cells.
Introduction
Curcumin [chemical name: 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepadiene-3,5 dione], is
a natural polyphenol component of turmeric (Curcuma longa) with demonstrated biological
activity against a wide assortment of human pathologies. Chemopreventive and therapeutic
properties of curcumin have been well established in vitro and in vivo for various types of
human cancer [1,2]. The ability of curcumin to act selectively on cancer cells over normal cells
highlights its potential as a useful cancer preventive or therapeutic modality with minimal
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toxicity [3]. However, the molecular mechanism by which curcumin influences various, seem-
ingly unrelated, signaling pathways to selectively obstruct aggressive cancer cells is unknown.
In previous reports, we showed that integrin β4 (ITG β4) is a target of curcumin in aggres-
sive breast cancer cells [4]. Curcumin inhibited ITG β4-dependent signaling events important
for breast cancer cell motility, invasion and anchorage-independent growth [4]. Our subse-
quent studies demonstrated that inhibition of ITG β4 signaling by curcumin is mediated by
blocking localization of ITG β4 to lipid raft membrane domains and disrupting its interaction
with growth factor receptors [5]. Mobilization of ITG β4 from hemidesmosomes into the lead-
ing edges and lipid rafts is thought to play an essential role for signaling competency of this
integrin [6–8].
Post-translational modifications of the ITG β4 cytoplasmic domain play an important role
in its trafficking and signaling competency. For example, a number of reports have shown that
phosphorylation of key tyrosine and serine residues along the cytoplasmic tail contributes to
hemidesmosome disassembly and subsequent activation of ITG β4 signaling in human cancer
cells [9–11]. ITG β4 is also palmitoylated on five cysteine residues (C732/736/738/739/742)
along a juxtamembrane segment of the cytoplasmic tail through a reversible thioester linkage
to regulate its signaling and trafficking [8, 9–11]. The palmitoylation of ITG β4 is catalyzed by
the palmitoyl acyltransferase DHHC3 [12, 13]. Palmitoylation of ITG β4 is necessary for incor-
poration of α6β4 into lipid rafts, where ITG β4 crosstalks with growth factor receptors and en-
hances invasive potential of cancer cells [5, 8]. Importantly, an alternative report suggests
palmitoylation of ITG β4 is not required for raft association, but rather for incorporation into
tetraspanin complexes [14]. In either scenario, the palmitoylation of ITG β4 mediates its traf-
ficking important for signaling competency.
In the present study, we examined the hypothesis that curcumin blocks ITG β4 trafficking
and signaling competency by blocking its palmitoylation. We demonstrated that curcumin
blocked the palmitoylation of ITG β4 in invasive breast cancer cells exhibiting high basal levels
of ITG β4 palmitoylation. Investigating the kinetics of ITG β4 palmitoylation in the context of
phosphorylation events, we were able to determine curcumin had a direct effect on palmitoyla-
tion. Further experimentation revealed curcumin inhibits palmitoylation of multiple proteins
by interfering with the autoacylation intermediate step of DHHC palmitoylating enzyme activ-
ity. Overall, this work supports a novel paradigm to explain the seemingly pleiotropic biological
activity of curcumin in aggressive cancer cells.
Experimental Procedures
Cell lines and reagents
MDA-MB-231 and MDA-MB-435, cells were obtained from the Lombardi Breast Cancer De-
pository at Georgetown University (Washington, DC). and were cultured in DMEM with 10%
fetal bovine serum and 1% antibiotics. Both HCC-1806 breast cancer cells, cultured in RPMI-
1640 with 10% fetal bovine serum, and MCF-10A breast epithelial cells, cultured in MEGM
containing 13 mg/ml BPE, 0.5mg hydrocortisone, 10 μg/ml hEGF, 5 mg/ml insulin and 100
ng/ml Cholera toxin (Lonza), were purchased from ATCC. All cell lines were maintained in
humidified incubators at 37°C in 5% CO2.
β4 Integrin (clone H-101), and actin (clone C-11) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz). GFP monoclonal antibody was obtained from Clontech.
Myc-tag (clone 71D10), Phospho-PKC (pan), Phospho-PKC α/β and Phospho-PKC δ were
purchased from Cell Signaling. Phospho-β4 integrin (Y1494) from ECM Biosciences. Flotilin-
2, Syntaxin-6 antibodies were from BD Transduction. DHHC3 (GODZ) antibody was pur-
chased from Abcam. Tubulin antibody was from Neo markers. Transferrin receptor antibody
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was from Invitrogen. Anti-GSH antibody, Dithiothreitol (DTT), N-ethylmaleimide (NEM),
hydroxylamine (HAM), curcumin, and 2-bromopalmitate were from Sigma-Aldrich. EZ-link
BMCC-Biotin and Streptavidin-HRP were purchased from Thermo Scientific. Tetrahydrocur-
cumin (THC) was provided by Dr. Surh (Research Institute of Pharmaceutical Sciences, Seoul
National University). For pharmacologic inhibition, Go6976 (PKC-α, -β, -γ isoforms inhibi-
tor), Go6983 (PKC-α, -β, -δ, -γ isoforms inhibitor) and BIM-1 (pan PKC inhibitor) were pur-
chased from Enzo Life Sciences. PP2 (Src inhibitor) was obtained from EMD chemicals Inc.
Plasmid constructions and transfection
Wild-type β4 integrin in the vector pRc/CMV was gift from Dr. Shaw Leslie. cDNA of β4 WT
was sub-cloned into the c-terminal GFP tagged pcDNA3 and Myc tagged pCMV-Tag 5 plas-
mid (Agilent Technologies) using standard techniques. Five cysteine mutations (C/A
732,736,738,739,742), triple serine mutations (S/A 1356,1360,1364) or S/A, S/D 1424 and sin-
gle serine mutations (Ser 1424 to Ala or Asp) of ITG β4 were made by Mutagenex, Inc (Piscat-
away, NJ). The constructs were digested by the EcoRI/SalI restriction sites and then sub-cloned
into the c-terminal GFP tagged pcDNA3 or Myc tagged pCMV- Tag 5. The expression plasmid
encoding HA tagged DHHC3 was purchased from the GeneCopoeia, Inc. All plasmids were
verified by sequencing (Macrogen USA) and western blotting. Transfection of the plasmids
was performed using Lipofectamine LTX-Plus (Invitrogen) according to the
manufacturer’s instruction.
Western analysis
Cells were lysed in cold RIPA-EDTA buffer [50 mMTris, pH 7.4; 150 mMNaCl; 1% NP-40;
0.5% sodium deoxycholate; 0.1% SDS; and 5 mM EDTA] containing 1 mM PMSF, 1 mM
Na3VO4, and protease inhibitor cocktail (Thermo Scientific, Rockford, IL). Protein concentra-
tions were determined using the BCA protein assay kit (Thermo Scientific). Samples diluted in
Laemmli running buffer with BME were separated by SDS/PAGE and transferred to PVDF
membrane (Bio-Rad, Hercules, CA). Membranes were incubated with primary antibodies in
TBS-T with 5% nonfat dry milk overnight at 4°C, washed and then incubated with appropriate
HRP-conjugated secondary antibodies. Proteins were detected using the pierce ECL western
blotting substrate (Thermo Scientific).
Invasion assay
Invasion assays were performed by a transwell cell culture chamber of 8 μm pore size (BD Fal-
con, Franklin Lakes, NJ) according to the standard procedure. Transwell inserts (8 μm pore
size) were coated with collagen I (15 μg/ml) overnight at 4°C. After washing with PBS, indicat-
ed cells (1x105cells/well) were treated with or without 15 μM curcumin added to the insert in
serum-free DMEM/BSA. Lysophosphatidic acid (LPA, 100 nM) was added to the lower cham-
ber in serum-free DMEM/BSA as a chemo-attractant. The chamber was incubated for 2.5
hours under cell culture conditions. Migrated cells attached to the underside of the membrane
were stained with crystal violet and counted. Assays were performed in triplicate and repeated
three times.
Acyl-Biotin Exchange
The acyl-biotin exchange technique was performed as previously described [15]. In brief, cells
were treated with or without curcumin for 5 hours prior to lysis (150mMNaCl, 5mM EDTA,
50mM Tris HCl, .02% NaN3, 2% Triton X-100, pH7.4, with Roche protease inhibitor cocktail).
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Equal protein was aliquoted for each sample and all unmodified free cysteine residues were co-
valently blocked by 50 mMN-ethylmaliamide treatment at pH 7.2 for 24 hours. Protein was
methanol-chloroform precipitated and washed 3 times in methanol. Protein was resuspended
in 1% SDS 50mM Tris-HCl pH 7.4 with or without hydroxylamine (HAM) for 1 hour at room
temperature rotating end-over-end to remove thioester-linked cysteine modifications. Protein
was again precipitated and washed. Now-free cysteines were bound by biotin (1 μM EZ-Link
Biotin-BMCC) at pH 7 for 24 hours at 4°C rotating. Protein was precipitated and washed be-
fore resuspending in non-reducing Laemmli buffer and boiling for 3 mins. Samples were sepa-
rated by SDS-PAGE and blotted with streptavidin-HRP to detect the presence of biotinylated
(S-acylated) protein.
Click chemistry-based detection of palmitoylated or nascent protein
Cell lines were grown to 80% confluency in 10 cm dishes. All dishes were pretreated with cul-
ture media containing 10% fatty acid free FBS (Gemini) with DMSO or 15 μM curucmin for 1
hour. Media is then replaced with fresh fatty acid free culture media containing alkyne-labeled
palmitic acid (17-ODYA, Caymen Chemicals) with or without 15 μM curcumin. Cells were in-
cubated for 4 hours to allow incorporation of labeled fatty acids. Cells were lysed in NP-40
buffer (25mM Tris-HCl, pH 7.4, 150mMNaCl, 1mM EDTA, 1% NP-40 and 5% glycerol with
Roche protease inhibitor cocktail tablets) at 4°C. Lysates are processed for 30 minutes with
end-over-end rotation at 4°C followed by removal of debris by centrifugation at 13,000xg for 5
minutes. Protein concentrations were determined and 200 μg of each sample was methanol-
chloroform precipitated. Precipitated protein was resuspended in 50 μl of 1% SDS reaction
buffer and the click chemistry reaction was performed according to the manufacturer's proto-
col using the Click-iT reaction buffer kit and corresponding biotin-based detection reagent
(Invitrogen). Following linkage of labeled fatty acid (17-ODYA) to biotin, protein was again
precipitated and resuspended in 100 μl of 1% SDS. Once protein was solubilized, SDS was di-
luted out with 1 mL of NP-40 buffer. Samples were precleared for 1 hour at 4°C with A/G
sepharose beads (Santa Cruz). After preclear, 100 μl of prewashed streptavidin-conjugated
sepharose beads were added to each sample to pull down biotinylated protein. Samples were
rotated end-over-end overnight at 4°C. Pull-down samples were washed 4 times in IP buffer,
before protein was eluted with 30 μl of Laemmli buffer containing BME. Samples were analyzed
by western blot using indicated antibodies.
For detection of newly synthesized protein, dishes were incubated in Methionine-free
growth media (Invitrogen) containing 10% FBS for 1 hour prior to treatments. Media was then
replaced with fresh Methionine-free growth media containing 10% FBS with or without 30 μM
azido-homoalanine (AHA) (Invitrogen) in the presence or absence or curcumin to label na-
scent proteins. Processing of lysates, click chemistry reaction, and pull-down of biotinylated
protein was performed as detailed above.
Results
Curcumin blocks palmitoylation of ITG β4
Our previous work showed that inhibition of ITG β4 signaling by curcumin is mediated
through blocking its lipid raft localization, thereby reducing its interaction with signaling re-
ceptors such as EGFR [4, 5]. However, a detailed molecular mechanism by which curcumin in-
hibits the mobilization of ITG β4 into the lipid rafts remains to be determined. Based on the
previous report that the lipid raft localization of ITG β4 requires palmitoylation of transmem-
brane proximal cysteine residues [8], we tested whether curcumin affected palmitoylation of
ITG β4. MDA-MB-231 cells were metabolically labeling with or without the alkyne-linked
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palmitate analogue, 17-ODYA [16,17], in the presence or absence of curcumin for 5 hours. Ly-
sates were processed through a click chemistry-based alkyne to biotin conjugation and strepta-
vidin-based pull-down assay to measure protein palmitoylation. As shown in Fig 1A, the
baseline palmitoylation level of ITG β4 was detected in MDA-MB-231 breast cancer cells, and
curcumin reduced ITG β4 palmitoylation similar to the level observed in cells treated with the
palmitoylation inhibitor 2-bromopalmitate (2BP). For each experiment, a no ODYA control is
included to indicate the non-specific background intensity following the click chemistry reac-
tion and streptavidin-based pull-down. In order to determine if curcumin was able to reverse
palmitoylation or simply block incorporation of labeled palmitate, cells were pulsed and chased
with or without 17-ODYA in the presence or absence of curcumin. The results indicated that
curcumin was consistently able to block palmitoylation of ITG β4, but was not able to reverse
the attachment of labeled palmitate (Fig 1B).
Blockade of ITG β4 palmitoylation by curcumin is more pronounced in
invasive breast cancer cells
Based on our previous study that curcumin inhibits cell motility and invasion in cancer cells
expressing signaling competent ITG β4 [5], we compared the effect of curcumin on ITG β4 pal-
mitoylation in an invasive breast cancer cell line (HCC-1806) and a non-invasive normal epi-
thelial cell line (MCF-10A). These two cell lines express comparable levels of ITG β4, but,
based on Y1494 phosphorylation status and previous reports, only the ITG β4 from HCC-1806
is in a signaling competent form under basal conditions (data not shown) [9, 18]. As shown in
Fig 2A, less ITG β4 was palmitoylated in the normal epithelial cell line MCF10A as compared
to palmitoylation levels observed from HCC-1806 cells. Similar to results fromMDA-MB-231
cells, curcumin reduced the level of ITG β4 palmitoylation in HCC-1806 cells, whereas it had
little effect on ITG β4 palmitoylation in MCF-10A cells particularly as the basal level of ITG β4
palmitoylation was already low (Fig 2A). Moreover, the ability of these two cell lines to invade
towards LPA in transwell assays trended with the palmitoylation levels of ITG β4 (Fig 2B).
These data further support a hypothesis that ITG β4 palmitoylation is important for the inva-
sive potential of cancer cells and provides a basis for the previously reported selective activity
of curcumin on invasive cancer cells over normal cells.
The unsaturated aliphatic chain of curcumin is essential for inhibition of
ITG β4 signaling and palmitoylation
Curcumin possess two aromatic rings connected by α\β-unsaturated carbonyl moieties [1,19].
These unsaturated double bonds in the aliphatic chains of curcumin have been shown to be
critical for its antioxidant and anticancer activity as well as its ability to undergo a Michael ad-
dition reaction with accessible cysteine residues [20–22]. To address the role curcumin’s unsat-
urated aliphatic chain in blocking ITG β4 palmitoylation and signaling competency, we
compared the effects of tetrahydro-curcumin (THC), a curcumin analogue with a saturated ali-
phatic chain, to curcumin [20, 21] (Fig 3A). Unlike curcumin, THC was unable to reduce
Y1494 phosphorylation of β4 (an indicator of ITG β4 signaling competency: Fig 3B) in
MDA-MB-231 cells or block invasion of the invasive breast cancer lines MDA-MB-231 and
SUM-225 (Fig 3C). Consistent with these findings, THC also failed to reduce palmitoylation
levels of ITG β4 in MDA-MB-231 cells to the same extent as curcumin (Fig 3D). Taken togeth-
er, these data indicate that the saturation status of the aliphatic chain in curcumin plays a criti-
cal role in obstructing ITG β4 signaling and palmitoylation.
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Fig 1. Curcumin inhibits palmitoylation of ITG β4. (A) MDA-MB-231 cells were pretreated with 15 μM curcumin or 100 μM 2-BP (2-bromopalmitate) for 1hr
prior to 17-ODYA labeling for 4 hr in the presence of either compound. (B) Cells were either treated with 15 μM curcumin1 hr before and during 17-ODYA
labeling for 3 hours, or labeled with 17-ODYA for 3 hours followed by wash and 4 hours chase treatment with 15 μM curcumin. Labeled proteins were reacted
to biotin-azide via click chemistry and biotinylated proteins were isolated using streptavidin-sepharose. Palmitoylated ITG β4 was detected by western blot
analysis using anti-β4 antibody. Representative blots of 3 independent experiments are displayed with relative input protein included. Densitometry is shown
in arbitrary units.
doi:10.1371/journal.pone.0125399.g001
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Integrin β4 palmitoylation does not require growth factor stimulation or
phosphorylation of its key Ser or Tyr residues
Given previous reports that curcumin can block several phosphorylation signaling cascades, it
was possible curcumin blocked palmitoylation indirectly by interfering with upstream
Fig 2. Inhibition of ITG β4 palmitoylation by curcumin is more effective in invasive cancer cells. (A)
MCF-10A and HCC-1806 cells pretreated for 1 hour with or without 15 μM curcumin and labeled with
17-ODYA for hours with or without 15 μM curcumin. Labeled proteins were reacted with biotin-azide via click
chemistry, isolated by streptavidin-sepharose, and analyzed by western blotting with anti-β4 antibody.
Results are representative of 3 independent experiments. Densitometry is shown in arbitrary units. (B) MCF-
10A and HCC-1806 cells were incubated with or without 15 μM curcumin. The ability of cells to invade toward
100 nM LPA was measured using a collagen-coated transwell assay. Invasion was quantified by counting
cells that migrated to the lower surface of the membrane per square milliliter using bright-field optics.
Columns, mean from three independent experiments; bars, SD. **, P < 0.01, versus control groups (without
curcumin).
doi:10.1371/journal.pone.0125399.g002
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signaling pathways [23]. To define the mechanism by which curcumin blocks palmitoylation,
we investigated the kinetics of ITG β4 palmitoylation in relation to growth factor stimulation
and phosphorylation status. Previous reports have demonstrated that ITG β4 activity and traf-
ficking is affected by epidermal growth factor (EGF) and hepatocyte growth factor (HGF) stim-
ulation through protein kinase C (PKC) and Src-family kinases [6–8, 10, 11, 18]. To assess
whether the kinetics of ITG β4 palmitoylation are even altered in response to these signaling
events, MDA-MB-231 cells were incubated with or without 17-ODYA in the presence or ab-
sence of EGF or HGF over the indicated time points. As shown in Fig 4A, the level of ITG β4
palmitoylation increased steadily even in the absence of growth factor stimulation. No fluctua-
tions in the rate of 17-ODYA incorporation were observed over time with or without EGF or
HGF stimulation (Fig 4A). A slight, yet inconsistent, reduction of ITG β4 palmitoylation was
observed at later time points. To further assess the involvement of ITG β4 phosphorylation on
the dynamics of its palmitoylation, we transfected GFP-tagged WT ITG β4; or phosphorylation
mutants of ITG β4, including serine mutants (triple Ser: S/A 1356,1382,1364; or S/A, S/D
1424); or a palmitoylation defective five cysteine mutant of ITG β4 (Cys 5: C/A
732,736,738,739,742) into MDA-MB-231 and incubated with 17-ODYA. As a negative control,
the cys 5 mutant was not labeled by 17-ODYA, confirming the authenticity of the assay and
that these 5 cysteines are the palmitoylation sites within ITG β4 (Fig 4B). In contrast, neither
Fig 3. The unsaturated aliphatic chain of curcumin is essential for inhibition of ITG β4 signaling and
palmitoylation. (A) Schematic illustrating structural differences between curcumin and THC emphasizing the
saturation state of the aliphatic chain. (B) MDA-MB-231 cells incubated with 10 μM curcumin or THC for 24
hours. Lysates were taken and western blot analysis was performed with immunoblotting for the indicated
proteins. (C)MCF-10A, MDA-MB-231, and SUM-225 cells were incubated with or without 15 μM curcumin or
15 μM THC. The ability of cells to migrate toward 100 nM LPA was measured using a transwell cell motility
assay. Invasion was quantified by counting cells that migrated to the lower surface of the membrane per
square milliliter using bright-field optics. Columns, mean from three independent experiments; bars, SD.
**, P < 0.01, versus control groups (without curcumin). (D) MDA-MB-231 cells were pretreated with 15 μM
curcumin or THC for 1hr prior to or during 4 hr of 17-ODYA labeling. Labeled proteins were reacted to biotin-
azide via click chemistry and biotinylated proteins were isolated using streptavidin-sepharose. Palmitoylated
ITG β4 was detected by western blot analysis using anti-β4 antibody. Representative blots of 3 independent
experiments are displayed with relative input protein included and densitometry shown in arbitrary units.
doi:10.1371/journal.pone.0125399.g003
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loss nor gain of function mutations of key ITG β4 serine residues affected ITG β4 palmitoyla-
tion (Fig 4B).
Knowing that PKC and Src-family kinases are inhibited by curcumin (Fig 4C) and that
these pathways are upstream of ITG β4 mobilization, we tested more closely the affect of their
inhibition on ITG β4 palmitoylation. MDA-MB-231 cells were pretreated with pharmacologi-
cal inhibitors of PKC isoforms Src-family kinases including Go6976 (an inhibitor of the con-
ventional isoforms of PKC-α, -β, -γ), Go6983 (an inhibitor of PKC-α, -β, -δ, -γ isoforms),
BIM-1 (an inhibitor of PKC pan), and PP2 (a Src-family kinase inhibitor) in the presence of
17-ODYA. As indicated in Fig 4D, neither PKC nor Src inhibition affected ITG β4 palmitoyla-
tion. Taken together these results suggest that ITG β4 palmitoylation is not influenced by
growth factor stimulation, phosphorylation status or upstream signaling in general.
Fig 4. Integrin β4 palmitoylation does not require growth factor stimulation or phosphorylation of its key Ser or Tyr residues. (A)MDA-MB-231 cells
were incubated in the presence of absence of 17-ODYA for the indicated times with or without 30 ng/ml HGF or 100 ng/ml EGF. (B) MDA-MB-231 cells were
transiently transfected with Wild-type β4-GFP, five Cysteine mutant (Mut 1: C/A 732,736,738,739,742), triple Serine mutant (Mut 2: S/A 1356,1382,1364) or
single Serine mutants (Mut 3: S/A 1424 and Mut 4: S/D 1424) prior to labeling with 17-ODYA. (C) MDA-MB-231 cells incubated with 10 μM curcumin for 24
hours. Lysates were taken and western blot analysis performed immunoblotting for the indicated proteins. (D) MDA-MB-231 cells were treated with Go6976
(2.5, 10 μM), Go6983 (2.5, 10 μM), BIM-1 (2.5 μM), or PP2 (10 μM) 1 hour prior to during 17-ODYA labeling for 5 hours. (E) MDA-MB-231 cells were
incubated with or without azido-homoalanine for the given time points in the presence or absence of 15 μM curcumin to label newly-synthesized protein. (A,B,
D,E) Labeled proteins were reacted with biotin-azide via click chemistry, isolated by streptavidin-sepharose, and analyzed by western blotting with indicated
antibody to assess palmitoylation. Representative blots of 3 independent experiments are displayed with relative input protein included. (F) MDA-MB-435
cells were transfected with the indicated myc- tagged integrin β4 construct. The ability of the mutants to migrated toward 100 nM LPA was measuring using a
transwell assay. Migration was quantified by counting cells that migrated to the lower surface of the membrane using bright-field optics. Columns, mean from
three independent experiments.
doi:10.1371/journal.pone.0125399.g004
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Given that ITG β4 palmitoylation seems to occur upon synthesis and this attachment re-
mains stable despite activating events, we tested whether curcumin was affecting the rate of β4
synthesis which could account for the observed reduced palmitoylation. Click chemistry based
assessment of ITG β4 synthesis in MDA-MB-231 cells revealed no consequential change to the
rate of its synthesis in the presence of curcumin (Fig 4E).
To demonstrate the effect each mutant construct has on cell motility, ITG β4-null
MDA-MB-435 breast cancer cells were transfected and assayed for ability to migrate through
collagen-coated transwell inserts. As shown in Fig 4F, exogenous expression of wt ITG β4 pro-
vides a significant increase in migratory potential. However, mutations preventing the palmi-
toylation of ITG β4 (Cys 5) greatly reduce this enhancement similar to phosphorylation
mutants that inhibit ITG β4 signaling capacity (triple Ser, S1424A, and Y1494F). Taken togeth-
er, these data indicate that phosphorylation and palmitoylation of ITG β4 are important for
its affect on cell motility; however, palmitoylation of ITG β4 is not dependent on its
phosphorylation.
Curcumin inhibits the palmitoylation of a subset of proteins without
indiscriminate blocking of global cysteine acylation
In order to determine how selective curcumin was at inhibiting protein palmitoylation, we per-
formed an acyl-biotin exchange technique to observe changes to global protein cysteine modifi-
cations in MDA-MB-231 cells following 24 hour incubation in the presence or absence of
curcumin. In this assay, acyl-groups thioester-linked to cysteine residues are exchanged for bio-
tin. Blotting for biotinylated protein by western blot revealed a banding pattern of whole cell
acylated proteins that changes little when taken fromMDA-MB-231 cells treatment with cur-
cumin (Fig 5A). Exclusion of the hydroxylamine (HAM) treatment step from the acyl-biotin
reaction is included as a negative control to indicate specificity of the biotin conjugation for
only acylated cysteine residues (HAM sensitive). Two protein loads are included for clarity of
the banding pattern. Somewhat surprisingly, these results further support that curcumin does
not indiscriminately inhibit all, or even a large portion of, protein palmitoylation. However,
immunoblotting for flotilin-2, a well characterized protein palmitoylated by DHHC5, as well as
transferrin receptor or syntaxin-6, palmitoylated by an undetermined DHHC enzyme, in sam-
ples from 17-ODYA-labeled MDA-MB-231 (flotilin-2 not detected) or HCC1806 cells (Fig 5B
upper and lower panels), indicated that curcumin was also able to reduce palmitoylation of ad-
ditional proteins and thus is not exclusively selective for ITG β4 [16, 24–26]. Under these con-
ditions and labeling time period, in HCC1806 cells, syntaxin-6 was not detected palmitoylated
and transferrin receptor was only modestly palmitoylated, as indicated by minimal enrichment
over No ODYA background.
Curcumin reduces autoacylation of the ITG β4 palmitoylating enzyme
DHHC3
To begin to define the mechanism by which curcumin interferes with palmitoylation of ITG
β4, and likely a subset of other proteins, we tested the possibility that curcumin inhibits the ac-
tivity of acyltransferases. The acyltransferase DHHC3 is required for palmitoylation of ITG β4
[13]. It is one of 22 members of the palmitoyl acytransferase (PAT) family of proteins which
transfer palmitate as palmitoyl-CoA to cysteines of substrate proteins [13, 27, 28]. This reaction
requires an autoacylation intermediate step prior to transfer of the acyl-group to the substrate
protein. We tested the effect of curcumin on DHHC3 expression and activity (autoacylation as
an indicator). Western blot analysis of MDA-MB-231 cells treated with curcumin over the in-
dicated time points revealed no change in the levels of DHHC3 protein (Fig 6A). However,
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when MDA-MB-231 cells transfected with HA-tagged DHHC3 (to overcome limiting expres-
sion levels of the native form) were incubated with 17-ODYA for 5 hours in the presence of
curcumin we found a great reduction in the palmitoylation of both native (data not shown)
and HA-tagged DHHC3 (Fig 6B). These data suggest that curcumin is able to block the inter-
mediate autoacylation step of DHHC3 activity which could account for the effects of curcumin
on select proteins including ITG β4.
Discussion
ITG β4 is a transmembrane receptor for extracellular matrix components that has been linked
with multiple cancer-associated phenotypes. Previous reports have demonstrated that palmi-
toylation of a series of cysteine residues influences function of this receptor either through
membrane domain localization or protein complex formation [8,14]. Given the importance of
this receptor in cancer cell growth, motility, and invasion; much effort has gone into finding
ways to inhibit its function [1,2,3,20]. Our previous reports have demonstrated the ability of
the polyphenol curcumin to disrupt trafficking of ITG β4 into lipid rafts and prevent its initia-
tion of a motile phenotype. We sought to better understand the mechanism by which curcumin
Fig 5. Curcumin does not indiscriminately block global cysteinemodifications, but does reduce palmitoylation of proteins beside Integrin β4. (A)
Acyl-biotin exchange was performed on protein fromMDA-MB-231 cells treated with or without 15 μM curcumin for 18 hours. The presence or absence of
hydroxylamine (HAM) during the reaction is used as a control for reaction specificity. Western blot analysis with streptavidin-HRP is shown depicting the
banding pattern of S-acylated proteins from 1 or 3 mg of total protein. (B) HCC1806 or MDA-MB-231 cells (upper and lower panels where indicated) were
pretreated with 15 μM curcumin for 1 hr prior to and during 5hr 17-ODYA labeling. Labeled proteins were reacted to biotin-azide via click chemistry and
biotinylated proteins were isolated using streptavidin-sepharose. Palmitoylated protein was detected by western blot analysis using indicated antibodies.
Representative blots of 3 independent experiments are displayed with relative input protein included and densitometry in arbitrary units.
doi:10.1371/journal.pone.0125399.g005
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affected ITG β4 function, and in so doing, discovered a potential unifying mechanism for the
seemingly pleiotropic effects of curcumin described in the literature.
Published reports have provided evidence that the unsaturated α,β-carbonyl groups of cur-
cumin facilitate binding to the nucleophilic sulfhydryl group of cysteine residues [22]. Cysteine
residues being the site of S-palmitoylation, provides rationale for curcumin acting as an inhibi-
tor of this post-translational modification. This hypothesis was tested using click chemistry-
based biotin labeling of palmitoylated proteins followed by a whole cell lysate biotin pull-
down. For all cell lines tested, curcumin was able to block, but not reverse, the palmitoylation
of ITG β4. While testing this hypothesis, we also observed that a cell line’s propensity for inva-
sion seemed to trend with the extent to which ITG β4 was palmitoylated in that cell line under
basal growth conditions. This potentially impactful observation will be elaborated in future
studies. In agreement with the original rationale, we found that a structural analog of curcumin
with a saturated aliphatic chain was a much weaker inhibitor of ITG β4 palmitoylation indicat-
ing the importance of the unsaturated α,β-carbonyl groups.
Little is known about the dynamics of ITG β4 palmitoylation, and to better understand how
curcumin could act to block this event, it was first necessary to test possible upstream influ-
ences. These experiments provided important negative results demonstrating the likelihood
that ITG β4 is stably palmitoylated along the biosynthetic pathway and is influenced little by
signaling events. Pharmacological inhibition of upstream signaling pathways, including PKC
and Src-family kinases, had no effect on ITG β4 palmitoylation. Similarly, loss and gain-of-
function mutations of key ITG β4 phosphorylation sites had no effect on its palmitoylation.
Growth factor stimulation did not substantially change the kinetics of ITG β4 palmitoylation;
Fig 6. Curcumin can block the autoacylation intermediate step of DHHC3 palmitoylating enzyme activity. (A) MDA-MB-231 cells were incubated with
15 μM curcumin over the indicated time points. Lysates were taken and western blot analysis was performed using indicated antibodies. (B) MDA-MB-231
cells transiently transfected with HA-tagged DHHC3 were pretreated with 15 μM curcumin for 1 hr prior to and during 5hr 17-ODYA labeling. Labeled proteins
were reacted to biotin-azide via click chemistry and biotinylated proteins were isolated using streptavidin-sepharose. Palmitoylated protein was detected by
western blot analysis using indicated antibodies. Representative blots of 3 independent experiments are displayed with relative input protein included and
densitometry in arbitrary units.
doi:10.1371/journal.pone.0125399.g006
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however, a marginal reduction was consistently observed at longer time points following HGF
treatment. These data indicate that curcumin does not block ITG β4 palmitoylation by inhibi-
tion of upstream phosphorylation cascades. The importance of these findings is highlighted by
the data demonstrating ITG β4 palmitoylation and phosphorylation are necessary for this
integrin to promote cell motility; however its phosphorylation is not a prerequisite for its
palmitoylation.
S-palmitoylation is catalyzed by the DHHC-family of palmitoyl acyltransferases with sub-
strate specificity differing between the 22 distinct DHHC-motif containing proteins. The cata-
lytic activity of DHHC proteins requires autoacylation of the cysteine within the DHHCmotif
prior to transfer of the palmitate to substrate proteins. Analyzing the acylation of DHHC3, we
found that curcumin was able to greatly reduce this intermediate step, and thereby prevent the
palmitoylation of ITG β4. In overexpressing DHHC3 one might expect elevated levels of palmi-
toylated ITG β4; however, given our observed seemingly co-translational palmitoylation of
ITG β4 we wouldn’t expect this to be true.
We performed an acyl-biotin exchange technique to globally assess thioester-linked cysteine
modifications and ask how promiscuously curcumin affected protein palmitoylation. The
banding pattern of whole cell palmitoylated proteins between treated and untreated cells was
unappreciable indicating a limited portion of proteins were affected and supporting a substan-
tial level of specificity for the effect of curcumin. However, we found that palmitoylation of flo-
tilin-2, syntaxin-6, and the transferrin receptor were also blocked by curcumin treatment.
These results suggest that curcumin is unlikely to indiscriminately block all protein lipidation,
but demonstrates some level of specificity for select proteins through inhibition of at least two
DHHC enzymes. We hypothesize the nucleophilic cysteine of the DHHCmotif of some, if not
all, PATs is susceptible to covalent bond formation with the unsaturated α,β-carbonyl groups
of curcumin, thereby blocking enzymatic palmitoylation of select proteins. It may be possible
that curcumin binds to more than just DHHC proteins to block palmitoylation; however, one
would expect that such a level of indiscriminate blockage, particularly at cysteine residues,
would have been detected by the acyl-biotin exchange experiment. Future studies will more di-
rectly test this hypothesis to determine the extent of curcumin specificity for PATs.
In conclusion, we have provided evidence that the palmitoylation status of ITG β4 is impor-
tant for cancer cell invasion and that palmitoylation of ITG β4 is a constitutive and stable event
that does not seem to be influenced by upstream signaling events. These data support ITG β4
palmitoylation being necessary for proper structure and function, but having little dynamic
regulatory responsibility with regard to activation and subcellular trafficking. Moreover, identi-
fying curcumin as an inhibitor of S-palmitoylation with some selectivity establishes a possible
unifying mechanism for at least some of curcumin’s seemingly pleiotropic effects.
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